Masciullo, V.; Susini, T.; Corrado, G.; Stepanova, M.; Baroni, A.; Renda, I.; Castiglione, F.; Minimo, C.; Bellacosa, A.; Chiofalo, B.;
et al. Nuclear Expression of β-Catenin Is Associated with Improved Outcomes in Endometrial Cancer. Diagnostics 2022, 12, 2401.
https://doi.org/10.3390/diagnostics12102401
AMA Style
Masciullo V, Susini T, Corrado G, Stepanova M, Baroni A, Renda I, Castiglione F, Minimo C, Bellacosa A, Chiofalo B,
et al. Nuclear Expression of β-Catenin Is Associated with Improved Outcomes in Endometrial Cancer. Diagnostics. 2022; 12(10):2401.
https://doi.org/10.3390/diagnostics12102401
Chicago/Turabian Style
Masciullo, Valeria, Tommaso Susini, Giacomo Corrado, Marina Stepanova, Alessandro Baroni, Irene Renda, Francesca Castiglione, Corrado Minimo, Alfonso Bellacosa, Benito Chiofalo,
and et al. 2022. "Nuclear Expression of β-Catenin Is Associated with Improved Outcomes in Endometrial Cancer" Diagnostics 12, no. 10: 2401.
https://doi.org/10.3390/diagnostics12102401
APA Style
Masciullo, V., Susini, T., Corrado, G., Stepanova, M., Baroni, A., Renda, I., Castiglione, F., Minimo, C., Bellacosa, A., Chiofalo, B., Vizza, E., & Scambia, G.
(2022). Nuclear Expression of β-Catenin Is Associated with Improved Outcomes in Endometrial Cancer. Diagnostics, 12(10), 2401.
https://doi.org/10.3390/diagnostics12102401
